MaaT Pharma Balance Sheet Health
Financial Health criteria checks 6/6
MaaT Pharma has a total shareholder equity of €25.6M and total debt of €11.5M, which brings its debt-to-equity ratio to 45%. Its total assets and total liabilities are €50.9M and €25.3M respectively.
Key information
45.0%
Debt to equity ratio
€11.52m
Debt
| Interest coverage ratio | n/a |
| Cash | €31.15m |
| Equity | €25.61m |
| Total liabilities | €25.31m |
| Total assets | €50.92m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 4RD's short term assets (€40.6M) exceed its short term liabilities (€14.7M).
Long Term Liabilities: 4RD's short term assets (€40.6M) exceed its long term liabilities (€10.6M).
Debt to Equity History and Analysis
Debt Level: 4RD has more cash than its total debt.
Reducing Debt: 4RD had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 4RD has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 4RD has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of 28.4% each year